Preoperative somatostatin receptor ligands (SRLs) treatment is proven to reduce GH and IGF1 levels (9) and induce tumor shrinkage (10), improving surgical outcomes in acromegaly (11, 12, 13). Here, GH1 is linked to acromegaly.